Outcomes of Intravenous Tocilizumab Treatment for Refractory Pars Planitis | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practiceRetrospective Study · 2015 · 41 citations
2Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study2024 · 34 citations
3Brief Report: A Prospective Open‐Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia RheumaticaCohort Study · 2016 · 125 citations
4Tocilizumab in Active, Moderate-to-Severe, Glucocorticoid-Resistant Thyroid Eye Disease: An Open-Label Prospective Study in Two Independent CohortsCohort Study · 2026 · 1 citations
5Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid TherapyRCT · 2022 · 133 citations
6Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational studyRetrospective Study · 2023 · 22 citations
7Effectiveness of tocilizumab without high-dose Glucocorticoids in patients with active Takayasu arteritis：a single center observational study2024
8Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialRCT · 2008 · 1,393 citations
9T-Cell–Engaging Bispecific Therapies and Ocular Inflammation Emerging Phenotypes, Immunologic Mechanisms, and Clinical ManagementOcular Immunology and Inflammation · 2026
10Ocular Manifestation of Mycoplasma-Induced Rash and Mucositis: A Case Series of Five PatientsOcular Immunology and Inflammation · 2026

More from Ocular Immunology and Inflammation

More from Harvard University